Welcome to the KLK2-comPAS Study
A study for people with hormone-resistant prostate cancer that has spread to other parts of the body (metastasized).
The KLK2-comPAS Study is testing how safe and effective the study drug is for people with hormone-resistant prostate cancer that has spread to other parts of the body (metastasized). Hormone-resistant prostate cancer means that the cancer is no longer responding to hormone therapy.
Everyone who participates in the study will be randomly assigned to receive the study drug or a placebo. A placebo looks like the study drug but has no active ingredients. In addition to the study drug or the placebo, all study participants will receive supportive care, which helps treat and manage symptoms.
The goal of this study is to test how well the study drug works to stop or slow your cancer compared to the placebo.
Hormone-resistant metastatic prostate cancer (mHRPC) is an advanced stage of prostate cancer that has spread beyond the prostate gland to other parts of the body (metastatic). Prostate cancer cells often need a male hormone called testosterone to grow. Hormone-resistant prostate cancer means that the cancer cells have learned to grow even when the amount of testosterone in the body is very low.
If you qualify for the study, you will be randomly assigned (like the flip of a coin) to get either the study drug (with supportive care) or a placebo (with supportive care).
Supportive care is the treatment and management of symptoms from your prostate cancer.
- There is a 2 in 3 (67%) chance of receiving the study drug, and a 1 in 3 (33%) chance of receiving the placebo.
- The study drug and the placebo are given by IV infusion over 30 to 60 minutes.
- This study is called a ‘blinded’ study, which means neither you nor the clinical staff will know if you are receiving the study drug or a placebo.
- You will receive the study treatment 3 times in the first cycle, and will continue to receive one dose every 6-week cycle until the study treatment period ends.
See if you may qualify
Answer the following questions to see if you or someone you know may be eligible to take part in this study.
Please keep in mind:
Even if you believe you meet the eligibility criteria, joining a clinical trial is not guaranteed. Whether you’re referred or able to take part depends on a review by a qualified healthcare professional.
Note about privacy:
Email responses may not be encrypted. This means there’s a chance the messages could be seen by someone other than the intended recipient. We will avoid including sensitive personal information in emails whenever possible. However, we cannot guarantee that no sensitive information will be revealed indirectly.
About your information:
With your consent, we will use your answers to help determine whether you may be eligible for this clinical trial. You can withdraw your consent at any time.
Your information may be transferred to countries outside your country of residence, including the United States, which may have different data protection rules.
If you submit any personal information about someone else, you confirm that you have permission to do so.
Please read our Privacy policy for more details.